Japanese regulator reviews first-line bladder cancer combination
Drug Discovery World
FEBRUARY 7, 2024
This submission brings us one step closer to the possibility of offering these patients a treatment that demonstrated improved survival and slowed disease progression compared to platinum-containing chemotherapy.” The sNDA is based on results from the Phase III EV-302 clinical trial.
Let's personalize your content